论文部分内容阅读
目的研究抗-VEGF和抗-EGFR药物吉非替尼治疗非小细胞肺癌的安全性及其临床疗效。方法选择2009年8月到2009年11月在我院就诊的36例非小细胞肺癌患者,其中女性患者19例,男性患者17例,每人每天均口服吉非替尼,每次250mg,每日1次。直到患者不能耐受时停止服药,观察患者生存期和不良反应情况,肿瘤无进展的时间,近期疗效。结果 36例患者最少服药一个月,其中服药后6例患者病情加重,l7例患者胸痛等症状有缓解,8例患者咳嗽,5例患者胸痛没有缓解。服药后不良反应有皮疹,厌食,恶心呕吐等。结论吉非替尼药物治疗非小细胞肺癌临床疗效较好,能提高多数患者的生存及生活质量。
Objective To study the safety and clinical efficacy of anti-VEGF and anti-EGFR gefitinib in the treatment of non-small cell lung cancer. Methods Thirty-six patients with non-small cell lung cancer who were treated in our hospital from August 2009 to November 2009 were selected. Among them, 19 were female and 17 were male. Gefitinib was given orally every day for 250 mg each 1 day. Until the patient can not tolerate medication, observe the patient’s survival and adverse reactions, tumor progression time, short-term efficacy. Results 36 patients took at least one month, of which 6 patients after taking the disease aggravated, l7 patients with symptoms such as chest pain relief, 8 patients cough, 5 patients did not relieve chest pain. Adverse reactions after taking rash, anorexia, nausea and vomiting. Conclusion Gefitinib treatment of non-small cell lung cancer clinical efficacy is better, can improve the survival and quality of life in most patients.